Comparative Pharmacology
Head-to-head clinical analysis: NEMBUTAL versus SECOBARBITAL SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEMBUTAL versus SECOBARBITAL SODIUM.
NEMBUTAL vs SECOBARBITAL SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and neuronal hyperpolarization. At high doses, has direct inhibitory effects on excitatory AMPA and kainate receptors.
Secobarbital enhances the activity of gamma-aminobutyric acid (GABA) at GABA-A receptors, increasing chloride ion influx and causing neuronal hyperpolarization, leading to CNS depression.
Induction of anesthesia: 50-120 mg IV as a single dose. Maintenance of anesthesia: additional doses of 20-40 mg IV as needed. For sedation (preoperative): 100-200 mg IM or 1-5 mg/kg IV 1-1.5 hours before procedure. For status epilepticus: loading dose of 5-15 mg/kg IV slow push, then 1-5 mg/kg/h IV infusion.
Oral: 100-200 mg at bedtime for insomnia; IM: 150-200 mg as a single dose; IV: 50-250 mg as a single dose, administered slowly (not to exceed 50 mg per 15 seconds).
None Documented
None Documented
Terminal elimination half-life is 40-120 hours (mean ~80 hours). The prolonged half-life contributes to accumulation with repeated dosing and residual sedation.
Terminal elimination half-life is approximately 15-40 hours (mean ~30 hours) in adults. In neonates, half-life may be prolonged (up to 100 hours). Half-life increases in hepatic impairment and with advanced age.
Renal elimination of unchanged drug accounts for approximately 30-35% of a dose; the remainder is hepatically metabolized. Less than 5% is excreted unchanged in feces.
Renal excretion of unchanged drug (about 25-50%) and metabolites; the remainder is eliminated via hepatic metabolism and fecal excretion. Less than 5% is excreted unchanged in feces.
Category C
Category D/X
Barbiturate
Barbiturate